S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
The Day of Financial Reckoning Is Near (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
The Safest Option in Trades! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
The Day of Financial Reckoning Is Near (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
The Safest Option in Trades! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
The Day of Financial Reckoning Is Near (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
The Safest Option in Trades! (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
The Day of Financial Reckoning Is Near (Ad)
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
The Day of Financial Reckoning Is Near (Ad)
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
The Safest Option in Trades! (Ad)pixel
NYSE:CRL

Charles River Laboratories International - CRL Stock Forecast, Price & News

$233.01
+6.54 (+2.89%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$225.72
$233.07
50-Day Range
$204.13
$250.54
52-Week Range
$203.37
$460.21
Volume
375,067 shs
Average Volume
581,073 shs
Market Capitalization
$11.85 billion
P/E Ratio
27.03
Dividend Yield
N/A
Price Target
$336.00

Charles River Laboratories International MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.77 Rating Score
Upside/​Downside
44.2% Upside
$336.00 Price Target
Short Interest
Healthy
1.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
-0.30mentions of Charles River Laboratories International in the last 14 days
Based on 33 Articles This Week
Insider Trading
Selling Shares
$45,226 Sold Last Quarter
Proj. Earnings Growth
14.94%
From $10.78 to $12.39 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.89 out of 5 stars

Medical Sector

47th out of 1,117 stocks

Commercial Physical Research Industry

3rd out of 17 stocks

CRL stock logo

About Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wall Street Analyst Weigh In

Several research analysts have issued reports on CRL shares. Guggenheim initiated coverage on Charles River Laboratories International in a research report on Monday, May 23rd. They issued a "neutral" rating for the company. They noted that the move was a valuation call. Deutsche Bank Aktiengesellschaft dropped their price objective on Charles River Laboratories International from $290.00 to $270.00 in a report on Monday, August 8th. KeyCorp dropped their price objective on Charles River Laboratories International from $390.00 to $300.00 in a report on Thursday, May 5th. Stephens set a $315.00 target price on Charles River Laboratories International in a research report on Monday, June 20th. Finally, Evercore ISI reduced their price objective on Charles River Laboratories International to $260.00 in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Charles River Laboratories International currently has a consensus rating of "Moderate Buy" and a consensus target price of $336.00.

Charles River Laboratories International Trading Up 2.9 %

Shares of Charles River Laboratories International stock traded up $6.54 on Friday, reaching $233.01. 375,067 shares of the company were exchanged, compared to its average volume of 581,073. The stock has a fifty day moving average price of $224.58 and a 200-day moving average price of $258.33. The firm has a market capitalization of $11.85 billion, a price-to-earnings ratio of 27.03, a price-to-earnings-growth ratio of 1.50 and a beta of 1.29. The company has a current ratio of 1.33, a quick ratio of 1.08 and a debt-to-equity ratio of 1.13. Charles River Laboratories International has a fifty-two week low of $203.37 and a fifty-two week high of $460.21.

Charles River Laboratories International (NYSE:CRL - Get Rating) last issued its earnings results on Wednesday, August 3rd. The medical research company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.74 by $0.03. Charles River Laboratories International had a return on equity of 21.51% and a net margin of 12.02%. The firm had revenue of $973.13 million for the quarter, compared to the consensus estimate of $995.12 million. During the same quarter in the previous year, the company posted $2.61 earnings per share. The business's quarterly revenue was up 6.4% compared to the same quarter last year. On average, analysts expect that Charles River Laboratories International will post 10.78 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 200 shares of the company's stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $226.13, for a total transaction of $45,226.00. Following the completion of the sale, the executive vice president now owns 20,766 shares in the company, valued at approximately $4,695,815.58. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.10% of the company's stock.

Receive CRL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

CRL Stock News Headlines

These 2 Stocks May Be Recession-Proof
See More Headlines
Receive CRL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.

CRL Company Calendar

Last Earnings
8/03/2022
Today
8/13/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
CUSIP
15986410
Employees
20,000
Year Founded
1947

Price Target and Rating

Average Stock Price Forecast
$336.00
High Stock Price Forecast
$480.00
Low Stock Price Forecast
$250.00
Forecasted Upside/Downside
+44.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

Net Income
$390.98 million
Pretax Margin
14.69%

Debt

Sales & Book Value

Annual Sales
$35.40 billion
Cash Flow
$16.23 per share
Book Value
$52.16 per share

Miscellaneous

Free Float
50,304,000
Market Cap
$11.85 billion
Optionable
Optionable
Beta
1.29

Social Links















CRL Stock - Frequently Asked Questions

Should I buy or sell Charles River Laboratories International stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last twelve months. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRL shares.
View CRL analyst ratings
or view top-rated stocks.

What is Charles River Laboratories International's stock price forecast for 2022?

13 Wall Street analysts have issued 1 year target prices for Charles River Laboratories International's shares. Their CRL share price forecasts range from $250.00 to $480.00. On average, they expect the company's stock price to reach $336.00 in the next year. This suggests a possible upside of 44.2% from the stock's current price.
View analysts price targets for CRL
or view top-rated stocks among Wall Street analysts.

How have CRL shares performed in 2022?

Charles River Laboratories International's stock was trading at $376.78 at the beginning of the year. Since then, CRL shares have decreased by 38.2% and is now trading at $233.01.
View the best growth stocks for 2022 here
.

Are investors shorting Charles River Laboratories International?

Charles River Laboratories International saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 976,900 shares, a decline of 7.0% from the July 15th total of 1,050,000 shares. Based on an average daily trading volume, of 509,000 shares, the days-to-cover ratio is presently 1.9 days. Approximately 1.9% of the shares of the stock are sold short.
View Charles River Laboratories International's Short Interest
.

When is Charles River Laboratories International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CRL earnings forecast
.

How were Charles River Laboratories International's earnings last quarter?

Charles River Laboratories International, Inc. (NYSE:CRL) announced its quarterly earnings results on Wednesday, August, 3rd. The medical research company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.74 by $0.03. The medical research company earned $973.13 million during the quarter, compared to analyst estimates of $995.12 million. Charles River Laboratories International had a net margin of 12.02% and a trailing twelve-month return on equity of 21.51%. The company's revenue was up 6.4% on a year-over-year basis. During the same period last year, the business earned $2.61 EPS.
Read the conference call transcript
.

What guidance has Charles River Laboratories International issued on next quarter's earnings?

Charles River Laboratories International issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of $10.70-$10.95 for the period, compared to the consensus earnings per share estimate of $11.53. The company issued revenue guidance of $3.86 billion-$3.93 billion, compared to the consensus revenue estimate of $4.01 billion.

What is James C. Foster's approval rating as Charles River Laboratories International's CEO?

291 employees have rated Charles River Laboratories International Chief Executive Officer James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Charles River Laboratories International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

What is Charles River Laboratories International's stock symbol?

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Who are Charles River Laboratories International's major shareholders?

Charles River Laboratories International's stock is owned by a number of retail and institutional investors. Top institutional investors include Kayne Anderson Rudnick Investment Management LLC (3.17%), FMR LLC (3.00%), Clearbridge Investments LLC (2.89%), William Blair Investment Management LLC (1.98%), Mackenzie Financial Corp (1.94%) and Allspring Global Investments Holdings LLC (1.27%). Insiders that own company stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Robert J Bertolini, Stephen D Chubb, Victoria L Creamer, William D Barbo and William D Barbo.
View institutional ownership trends
.

How do I buy shares of Charles River Laboratories International?

Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Charles River Laboratories International's stock price today?

One share of CRL stock can currently be purchased for approximately $233.01.

How much money does Charles River Laboratories International make?

Charles River Laboratories International (NYSE:CRL) has a market capitalization of $11.85 billion and generates $35.40 billion in revenue each year. The medical research company earns $390.98 million in net income (profit) each year or $8.62 on an earnings per share basis.

How many employees does Charles River Laboratories International have?

The company employs 20,000 workers across the globe.

Does Charles River Laboratories International have any subsidiaries?

The following companies are subsidiares of Charles River Laboratories International: 3313290 Nova Scotia Company, 9904140 Canada Inc., Accugenix Inc., Agilux Laboratories, Argenta Discovery 2009 Limited, Ballardvale C.V., Beijing Vital River Laboratory Animal Technology Co. Ltd., BioFocus DPI (Holdings) Ltd., Biological Laboratories Europe Ltd. ("BioLabs"), Blue Stream Laboratories, Brains On-Line, CRL Dutch Holding Company B.V., CRL Group France, CRL Group International France, CRL Holding Germany GmbH, CRL Holding Netherlands B.V., CRL Safety Assessment Inc., Celsis Group Limited, Celsis International, Celsis International B.V., Celsis International GmbH, Celsis International Limited, Celsis Limited, Cerebricon, Chantest, Charles River Detecção Microbiana e de Endotoxina Participações Ltda, Charles River Discovery Research Services Finland, Charles River Discovery Research Services Germany GmbH, Charles River Discovery Research Services Inc., Charles River Discovery Research Services International Inc., Charles River Discovery Research Services UK Limited, Charles River Endotoxin Microbial Detection Europe SAS, Charles River Endotoxin and Microbial Detection Israel, Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd., Charles River Germany GmbH & Co. KG, Charles River Germany Verwaltungs GmbH, Charles River Holdings LLC, Charles River Laboratories Ashland LLC, Charles River Laboratories Asia Holdings Limited, Charles River Laboratories Australia Pty. Ltd., Charles River Laboratories Belgium SPRL, Charles River Laboratories Cleveland Inc., Charles River Laboratories Copenhagen, Charles River Laboratories Den Bosch B.V., Charles River Laboratories Edinburgh Ltd., Charles River Laboratories España SA, Charles River Laboratories Evreux, Charles River Laboratories France Safety Assessment SAS, Charles River Laboratories France-C.R.L.F. SAS, Charles River Laboratories Germany GmbH, Charles River Laboratories Group, Charles River Laboratories Holding Europe SAS, Charles River Laboratories Holding SAS, Charles River Laboratories Holdings Limited, Charles River Laboratories Hungary, Charles River Laboratories I Delaware Holdings Inc., Charles River Laboratories II Delaware Holdings Inc., Charles River Laboratories Inc., Charles River Laboratories India Private Limited, Charles River Laboratories Ireland Holding Unlimited Company, Charles River Laboratories Ireland Limited, Charles River Laboratories Italia Srl, Charles River Laboratories Japan Inc., Charles River Laboratories Korea, Charles River Laboratories Luxembourg S.a.r.l., Charles River Laboratories Montreal ULC, Charles River Laboratories Poland Sp. Z.o.o., Charles River Laboratories Research Models and Services Germany GmbH, Charles River Laboratories SA France Acquisition SAS, Charles River Laboratories SA France Holdings SAS, Charles River Laboratories SA Japan KK, Charles River Laboratories SA Netherlands Holdings B.V., Charles River Laboratories SA USA Inc., Charles River Laboratories Saint Nazaire, Charles River Laboratories Saint‑Constant S.A., Charles River Microbial Solutions Company (Shanghai) Limited, Charles River Microbial Solutions International Limited, Charles River Nederland B.V., Charles River UK Limited, Charles River ULC, CiToxLAB, Citox Inc., Citoxlab USA LLC, Cognate BioServices, Genetic Models, HemaCare, Inveresk Research, KWS BioTest, KWS BioTest Limited, MPI Research, Molecular Therapeutics, Nastor Investments, NewLab BioQuality AG, Northwest Kinetics, Oncotest, Pathology Associates International Corporation, Piedmont Research Center, Primedica, Retrogenix Limited, River Valley Farms, Saothorlanna Bitheolaiocha Idirnaisiunta Teoranta, Sierra Biomedical, Solvo Biotechnology USA Inc., Solvo Biotechnológiai Zrt, Springborn Laboratories, Sunrise Farms Inc., Systems Pathology Company LLC, Tektagen Inc, Vigene Biosciences Inc., WIL Research, Zhanjiang A&C Biological Ltd., and Zhejiang Vital River Laboratory Animal Technology Co. Ltd..
Read More

When was Charles River Laboratories International founded?

Charles River Laboratories International was founded in 1947.

How can I contact Charles River Laboratories International?

Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The official website for the company is www.criver.com. The medical research company can be reached via phone at (781) 222-6000, via email at askcharlesriver@crl.com, or via fax at 978-988-5665.

This page (NYSE:CRL) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.